Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Marie Skłodowska-Curie Action · Running

nanoGET Nanopore based evaluation of genomic, epigenetic and transcriptomic impact of gene editing

Coordinator
Kobenhavns Universitet, Denmark
Runs
1 May 2027 to 30 April 2029
Status
Running
EU funding
€248k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101282451

What the project is doing

In the project's own words, from its summary on CORDIS.

Genome editing technologies such as CRISPR/Cas9 have transformed biomedical research and hold great therapeutic promise. Current safety evaluation strategies focus primarily on genomic alterations—off-target mutations, large deletions, and chromosomal rearrangements while largely overlooking transcriptomic and epigenomic consequences. Moreover, safety profiling is fragmented across multiple platforms, limiting accessibility and routine implementation.

This project, nanoGET, will establish a comprehensive, single-platform pipeline for safety evaluation of genome editing using nanopore sequencing which uniquely enables long-read sequencing of both DNA and RNA while simultaneously detecting base modifications, allowing integrated analysis of genomic, transcriptomic, and epigenetic changes within a single workflow. The pipeline will benchmark ONT against gold-standard methods for off-target detection, large deletions, DNA methylation profiling, chromatin accessibility, and transcriptomics.

Using human iPSCs, the project will systematically evaluate the consequences of editing across the three layers. A key innovation is the direct comparison of double-strand break (DSB)-mediated editors (Cas9) with DSB-free approaches (base and prime editors), generating the first integrated dataset to quantify multi-layered differences between editing modalities. By delivering an affordable, scalable, and standardized pipeline, nanoGET will provide novel insights into unintended consequences of editing, enable rational selection of editing methods, and accelerate the development of safer therapeutic strategies.

Beyond research impact, this platform will expand access to high-quality safety evaluation worldwide, strengthening scientific progress, innovation, and public trust in genome editing.

Topics

Who is involved

OrganisationCityCountryRole
Kobenhavns UniversitetKobenhavnDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI